XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Partners with Agora Internet Relations Corp. for Its Marketing and Advertising

• XPhyto partners with AGORA t to grow its brand and overall market share
• The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021
• AGORA is known for its online marketing, conferences, broadcasting and investor relations services
• Its clients include CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) just announced that it is following through with its advertising agreement with AGORA Internet Relations Corp (“AGORA”) that dates back to December 1, 2020.

The agreement entails shares issued to AGORA on August 21, 2021 and December 31, 2021 at a price of $2.12 per share, subject to a hold period that ends on October 18, 2021 with respect to the various applicable securities legislation. With this move, AGORA now holds 20,549 common shares of XPhyto, equivalent to 0.03% of the issued and outstanding common shares (https://ibn.fm/GVoHm).

AGORA is known for its online marketing, conferences, broadcasting and investor relations services for the global market. With its online community, AGORA is able to help investors and small companies to not only discuss but also discover small cap stocks and investment opportunities (https://ibn.fm/BgDHx). Its client list is constantly growing and is currently made up of companies such CardioComm Solutions, Good Life Networks, Northern Sphere, Grizzly Discoveries and IntellaEquity Inc., among others (https://ibn.fm/cuUyv). XPhyto plans on capitalizing on the experience that AGORA has by working with the other clients and leveraging on this to grow its brand and overall market share.

XPhyto is a life sciences technology accelerator, focusing on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. Its biggest achievement so far has been its rapid COVID-19 PCR test kit that reduces test turnaround times to less than 30 minutes (https://ibn.fm/KELop). The company has operations in Europe and North America, with an operational focus in Germany.

This partnership with AGORA has the potential to push the XPhyto brand even further, allowing it to appeal to more customers and fulfil its agenda for growth and commercialization for the European market.

For more information, visit the company’s website at www.XPhyto.com.

NOTE TO INVESTORS: The latest news and updates relating to XPHYF are available in the company’s newsroom at https://ibn.fm/XPHYF 

About BioMedWire

BioMedWire (BMW) is a bio-med news and content distribution company that provides (1) access to a network of wire services via InvestorWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with BMW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information, please visit https://www.biomedwire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork.